These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27323109)

  • 21. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
    Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
    Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer.
    Booton R; Ward T; Heighway J; Ashcroft L; Morris J; Thatcher N
    J Thorac Oncol; 2006 Sep; 1(7):679-83. PubMed ID: 17409936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh.
    Bushra MU; Rivu SF; Sifat AE; Nahid NA; Ahmed MU; Al-Mamun MMA; Apu MNH; Islam MS; Islam MR; Islam MS; Hasnat A
    Mol Biol Rep; 2020 Sep; 47(9):7073-7082. PubMed ID: 32880833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of GSTs gene polymorphisms with treatment outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
    Wu G; Jiang B; Liu X; Shen Y; Yang S
    Int J Clin Exp Pathol; 2015; 8(10):13346-52. PubMed ID: 26722539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.
    Liu YP; Ling Y; Qi QF; Zhang YP; Zhang CS; Zhu CT; Wang MH; Pan YD
    Mol Med Rep; 2013 Jun; 7(6):1904-11. PubMed ID: 23604281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.
    Sun N; Sun X; Chen B; Cheng H; Feng J; Cheng L; Lu Z
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):437-46. PubMed ID: 19568750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphisms in metabolic GSTP1 and DNA-repair XRCC1 genes with an increased risk of DNA damage in pesticide-exposed fruit growers.
    Wong RH; Chang SY; Ho SW; Huang PL; Liu YJ; Chen YC; Yeh YH; Lee HS
    Mutat Res; 2008 Jul; 654(2):168-75. PubMed ID: 18603015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
    Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
    Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.
    Chen J; Zhao QW; Shi GM; Wang LR
    J Zhejiang Univ Sci B; 2012 Nov; 13(11):875-83. PubMed ID: 23125080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between polymorphisms in the XRCC1 gene and the risk of non-small cell lung cancer.
    Han JC; Zhang YJ; Li XD
    Genet Mol Res; 2015 Oct; 14(4):12888-93. PubMed ID: 26505441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma.
    Lu C; Spitz MR; Zhao H; Dong Q; Truong M; Chang JY; Blumenschein GR; Hong WK; Wu X
    Cancer; 2006 Jan; 106(2):441-7. PubMed ID: 16342067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
    Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
    Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of CYP1A1, GSTP1 and XRCC1 genes polymorphisms on toxicity and response to chemotherapy in childhood acute lymphoblastic leukemia.
    Abo-Bakr A; Mossallam G; El Azhary N; Hafez H; Badawy R
    J Egypt Natl Canc Inst; 2017 Sep; 29(3):127-133. PubMed ID: 28844589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy.
    Zhang L; Ma W; Li Y; Wu J; Shi GY
    Genet Mol Res; 2014 Jan; 13(1):228-36. PubMed ID: 24446315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive potential role of glutathione S-transferases polymorphisms in response to chemotherapy and breast cancer prognosis.
    Yuan P; Yuan L; Xu BL; Wang CZ; Yang HZ; Li Y
    Genet Mol Res; 2015 Dec; 14(4):16675-81. PubMed ID: 26681014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population.
    Han ZG; Tao J; Yu TT; Shan L
    Med Sci Monit; 2017 Apr; 23():1999-2006. PubMed ID: 28442702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer].
    Wang ZH; Miao XP; Tan W; Zhang XR; Xu BH; Lin DX
    Ai Zheng; 2004 Aug; 23(8):865-8. PubMed ID: 15301704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms.
    Liu G; Zhou W; Park S; Wang LI; Miller DP; Wain JC; Lynch TJ; Su L; Christiani DC
    Cancer; 2004 Dec; 101(12):2802-8. PubMed ID: 15534883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glutathione S-Transferase Gene Polymorphisms are Associated with an Improved Treatment Response to Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis.
    Wang H; Gao X; Zhang X; Gong W; Peng Z; Wang B; Wang L; Chang S; Ma P; Wang S
    Med Sci Monit; 2018 Oct; 24():7482-7492. PubMed ID: 30341887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.